UBS Group AG raised its stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Free Report) by 97.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 192,191 shares of the company’s stock after buying an additional 94,829 shares during the period. UBS Group AG’s holdings in Bicara Therapeutics were worth $3,235,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. acquired a new position in Bicara Therapeutics during the 4th quarter valued at about $150,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Bicara Therapeutics during the 4th quarter valued at about $45,000. SG Americas Securities LLC acquired a new position in Bicara Therapeutics during the 4th quarter valued at about $187,000. Tudor Investment Corp ET AL acquired a new position in Bicara Therapeutics during the 3rd quarter valued at about $296,000. Finally, Cantor Fitzgerald L. P. acquired a new position in Bicara Therapeutics during the 3rd quarter valued at about $1,579,000.
Insider Activity
In other news, COO Ryan Cohlhepp sold 12,500 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $20.29, for a total transaction of $253,625.00. Following the sale, the chief operating officer owned 191,641 shares in the company, valued at $3,888,395.89. The trade was a 6.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 9,200 shares of the business’s stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an average price of $23.00, for a total transaction of $211,600.00. Following the sale, the chief financial officer owned 145,355 shares in the company, valued at $3,343,165. This represents a 5.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 186,810 shares of company stock worth $3,712,908 over the last three months. 15.50% of the stock is owned by insiders.
Bicara Therapeutics Price Performance
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). As a group, equities research analysts forecast that Bicara Therapeutics Inc. will post -3.37 EPS for the current fiscal year.
Analysts Set New Price Targets
BCAX has been the topic of several recent research reports. Wall Street Zen raised shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday. Morgan Stanley lifted their price objective on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. HC Wainwright lifted their price objective on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Bank of America initiated coverage on shares of Bicara Therapeutics in a research note on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Wednesday, April 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bicara Therapeutics has an average rating of “Moderate Buy” and an average price target of $30.27.
Check Out Our Latest Stock Analysis on BCAX
Bicara Therapeutics Company Profile
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Featured Articles
- Five stocks we like better than Bicara Therapeutics
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding BCAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bicara Therapeutics Inc. (NASDAQ:BCAX – Free Report).
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
